INTRA- MAMMARY DISTRIBUTION OF TRANSERMAL TELAPRISTONE VERSUS ORAL TELAPRISTONE VERSUS ORAL TELAPRISTONE: A RANDOMIZED WINDOW TRAIL IN WOMEN UNDERGOING MASTECTOMY 08/26/2014 -02/25/2017
INTRA- MAMMARY DISTRIBUTION OF TRANSERMAL TELAPRISTONE VERSUS ORAL TELAPRISTONE VERSUS ORAL TELAPRISTONE: A RANDOMIZED WINDOW TRAIL IN WOMEN UNDERGOING MASTECTOMY 08/26/2014 -02/25/2017
批准号:
8948683
负责人:
RAYMOND BERGAN
金额:
$83.23万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-08-26 至 2017-02-25
关键词:
AddressAftercareApoptosisBreastBreast Cancer PreventionCell ProliferationChicagoClinical TrialsCore BiopsyDiagnosticDouble-Blind MethodFamilyGelGene ExpressionGoalsLabelMalignant NeoplasmsMammary Gland ParenchymaMammary glandMastectomyMeasuresMemorial Sloan-Kettering Cancer CenterMutationOperative Surgical ProceduresOralOral AdministrationPhasePlasmaProgesteroneProgesterone ReceptorsProphylactic treatmentProtein IsoformsRandomizedRecording of previous eventsResearchSafetySamplingSerumStagingTNFSF10 geneTissue SampleTopical agentTransdermal substance administrationUniversitiesVariantWomancancer therapycaspase-3drug distributionindexinglobular breast carcinoma in situmalignant breast neoplasmmutation carrierprophylacticprotein expression
中文摘要
拟议的临床试验应解决局部药物用于乳腺癌预防的一个主要问题——药物在整个乳房的分布。目的是确定口服和局部给药是否在整个乳房组织中有相似的替拉匹司酮浓度。
英文摘要
The proposed clinical trial shall address a major question in the use of topical agents for breast cancer prevention – drug distribution throughout the breast. The goal is to determine if there are similar breast tissue concentrations of telapristone throughout the breast with both oral and topical delivery.
It is a phase IIb randomized double-blinded trial of oral vs. topical telapristone for 4 weeks prior to surgery in women undergoing mastectomy for stage 0-II breast cancer therapy or prophylaxis (for BRCA mutation, BRCA mutation carriers, women with strong family history or lobular carcinoma in situ or other conditions where prophylactic mastectomy has been elected) at Northwestern University, University of Chicago, and Memorial Sloan Kettering Cancer Center.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Contract HHSN261201200035I, Cancer Prevention Agent Development Program: Early Phase Clinical Research, 9/24/2012 - 9/23/2017Task Order HHSN26100005, Phase I Trial of Berberine in Subjects with U
-
批准号:8948660
-
项目类别:
-
资助金额:$7.79万
-
财政年份:2014
-
负责人:RAYMOND BERGAN
-
依托单位:
PROTOCOL NWU2013-02-01A PHASE I TRIAL OF INHALED ILOPROST FOR THE PREVENTION OF LUNG CANCER IN FORMER SMOKERS
-
批准号:8948677
-
项目类别:
-
资助金额:$54.5万
-
财政年份:2014
-
负责人:RAYMOND BERGAN
-
依托单位:
Contract HHSN261201200035I, 09/24/2012 - 09/23/2017Cancer Prevention Agent Development Program: Early Phase Clinical ResearchTask Order HHSN25100006, 09/24/2014 - 09/23/2015Core Infrastructur
-
批准号:8948583
-
项目类别:
-
资助金额:$61.83万
-
财政年份:2014
-
负责人:RAYMOND BERGAN
-
依托单位:
Phase 1 and Phase 2 Clinical Trials of Agents for Cancer Prevention
-
批准号:7947670
-
项目类别:
-
资助金额:$170.5万
-
财政年份:2003
-
负责人:RAYMOND BERGAN
-
依托单位:
海外基金